Pseudarthrosis

1. GLP-1 receptor agonists have no effect on pseudarthrosis in humans (OR 0.86, 95% CI 0.56-1.32).

   Reviewin ACDF (MarketScan)

   GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 24 Aug 2026

GLP-1 receptor agonists →

1. GLP-1 receptor agonists lower the risk of pseudarthrosis in humans.

   Humansfollowing ACDF surgerywithin 2 years

   GLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects · Journal of neurosurgery. Spine · 28 Aug 2026

2. GLP-1 receptor agonists lower the risk of pseudarthrosis in humans (OR 0.52, 95% CI 0.40-0.67).

   Reviewin ACDF (TriNetX)

   GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 24 Aug 2026

GLP-1 receptor agonists →

1. Semaglutide raises the risk of pseudarthrosis in humans (OR 4.79, 95% CI 3.11-7.37).

   Reviewin posterior cervical fusion (PCF)2-year

   GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 24 Aug 2026

Semaglutide →